The strength of the relationship between therapists and patients appears to play a crucial role in the effectiveness of MDMA-assisted psychotherapy in treating posttraumatic stress disorder (PTSD), according to new research published in the European Journal of Psychotraumatology. The findings provide evidence that a stronger therapeutic alliance correlates with better treatment outcomes for patients.
PTSD is a mental health condition that can develop after an individual experiences or witnesses a traumatic event, such as warfare, a natural disaster, a serious accident, or physical or sexual assault. Characterized by intense, disturbing thoughts and feelings related to the traumatic experience, individuals with PTSD often relive the event through flashbacks or nightmares, leading to feelings of sadness, fear, or anger, and a sense of detachment or estrangement from other people.
They may also experience heightened reactions to stimuli, trouble sleeping, and severe anxiety, which can persist for months or years after the traumatic event. The impact of PTSD can be profound, affecting a person’s ability to function in daily life and maintain relationships.
Despite existing treatments for PTSD, including psychotherapy and medications, many individuals continue to struggle with the disorder. Traditional treatments have limitations, and some patients do not respond well or drop out. This gap in treatment efficacy led researchers to explore alternative methods like MDMA-assisted psychotherapy, which had shown promise in earlier trials.
MDMA, commonly known by its street name “ecstasy,” is a synthetic drug known for its psychoactive effects, including heightened sensations, increased energy, and emotional openness. MDMA-assisted psychotherapy represents a novel approach to treating PTSD. It involves administering MDMA in a controlled, clinical setting, combined with psychotherapy sessions. This method aims to create a supportive environment where patients can process traumatic memories more effectively, potentially leading to significant improvements in their condition.
“MDMA-assisted psychotherapy, which combines the administration of a drug with psychotherapy, is showing increasing promise as a treatment for posttraumatic stress disorder,” explained lead author Richard Zeifman, a postdoctoral fellow in the NYU Langone Center for Psychedelic Medicine.
“However, there remains limited understanding and significant debate surrounding the importance of the psychotherapeutic component of the treatment. Because therapeutic alliance is the most central ingredient within psychotherapy, we were interested in examining its importance within MDMA-assisted psychotherapy.”
For their study, used data from a previously conducted clinical trial that enrolled 22 individuals with chronic PTSD. Participants had previously tried other treatments without success and were predominantly female (77.3%) and all Caucasian, with an average age of 57.5 years.
The study was structured into two phases. The first phase was a double-blind, randomized controlled phase where participants were divided into two groups. One group received MDMA (125 mg with an optional half-dose supplement), and the other received a placebo, alongside psychotherapy sessions. The second phase was an open-label phase, where participants initially given a placebo could opt for MDMA sessions.
The treatment protocol encompassed preparatory psychotherapy sessions, experimental sessions with MDMA or placebo administration, and post-dosing integration sessions. The entire process was supervised by a team of male and female co-therapists, adhering to a comprehensive treatment manual designed specifically for MDMA-assisted psychotherapy.
The study’s focal point was evaluating the therapeutic alliance, which refers to the collaborative relationship between a patient and their therapist. This was measured using the Working Alliance Inventory (WAI), a validated tool that assesses the bond, agreement on goals, and agreement on tasks between the therapist and patient.
To gauge the severity of PTSD symptoms, the researchers employed two methods: clinician assessments using Clinician-Administered PTSD Scale (CAPS) and self-reported measures using the Impact of Event Scale-Revised (IES-R). These tools provided a robust picture of the participants’ PTSD symptoms from both clinical and personal perspectives.
The study’s primary revelation concerns the importance of the therapeutic alliance. The researchers found that the strength of this alliance, particularly in the middle and later stages of therapy, was a significant predictor of treatment efficacy. Specifically, the therapeutic relationship’s quality during the fourth and ninth therapy sessions was crucial. It significantly influenced the reduction in PTSD symptoms, as measured both by clinicians and by the patients themselves.
For clinician-assessed PTSD severity, the therapeutic alliance at these sessions accounted for 24-29% of the variance in treatment outcomes. This finding indicates a substantial impact, suggesting that as the therapy progressed, the patient-therapist bond was important in contributing to the treatment’s success.
In terms of self-reported PTSD severity, the therapeutic alliance at sessions four and nine was again significant. It accounted for 26-40% of the variance in post-treatment symptom severity. This high percentage underscores the importance of patients’ perception of their relationship with their therapists in determining how they experience their own progress.
Interestingly, the study found that the strength of the therapeutic alliance at the baseline — before the MDMA-assisted sessions began — did not significantly predict the treatment outcomes. This finding suggests that the initial rapport between patient and therapist, while important for general therapy dynamics, may not be as crucial in determining the specific outcomes of MDMA-assisted therapy as the relationship that develops during the treatment.
The researchers also explored whether there were any significant differences in the therapeutic alliance based on gender. The findings revealed no statistical differences between male and female participants in terms of how they perceived the therapeutic alliance at any stage of the treatment. This consistency across genders suggests that the importance of the therapeutic alliance in MDMA-assisted psychotherapy is a broadly applicable factor, regardless of the patient’s gender.
These results underscore the importance of the therapeutic relationship in MDMA-assisted psychotherapy. It suggests that for patients undergoing this treatment, the connection and trust built with their therapists can be a critical factor in their recovery journey. The findings advocate for therapists to focus on building a strong, supportive relationship with their patients, especially as the therapy progresses.
“MDMA-assisted psychotherapy is not a traditional treatment in which individuals are administered a drug,” Zeifman told PsyPost. “Rather, it appears to be the drug in combination with psychotherapy that is helpful, especially when there is a strong relationship between the individual receiving treatment and their therapists.”
While the study provides valuable insights, it also has its limitations. The sample size was relatively small and lacked diversity, consisting mostly of Caucasian females. This limitation raises questions about the generalizability of the findings to broader populations. Future research could include a more diverse participant group and use a broader range of measures to gain a more comprehensive understanding of the therapeutic alliance’s role in MDMA-assisted psychotherapy.
The study, “Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder“, was authored by Richard J. Zeifman, Hannes Kettner, Stephen Ross, Brandon Weiss, Michael C. Mithoefer, Ann T. Mithoefer, and Anne C. Wagner.
